A transgenic minipig model of Huntington’s disease shows early signs of behavioral and molecular pathologies

ABSTRACT Huntington9s disease (HD) is a monogenic, progressive, neurodegenerative disorder with currently no available treatment. The Libechov transgenic minipig model for HD (TgHD) displays neuroanatomical similarities to humans and exhibits slow disease progression, and is therefore more powerful than available mouse models for the development of therapy. The phenotypic characterization of this model is still ongoing, and it is essential to validate biomarkers to monitor disease progression and intervention. In this study, the behavioral phenotype (cognitive, motor and behavior) of the TgHD model was assessed, along with biomarkers for mitochondrial capacity, oxidative stress, DNA integrity and DNA repair at different ages (24, 36 and 48 months), and compared with age-matched controls. The TgHD minipigs showed progressive accumulation of the mutant huntingtin(mHTT) fragment in brain tissue and exhibited locomotor functional decline at 48 months. Interestingly, this neuropathologyprogressed without any significant age-dependent changes in any of the other biomarkers assessed. Rather, we observed genotype-specific effects on mitochondrial DNA (mtDNA) damage, mtDNA copy number, 8-oxoguanine DNA glycosylaseactivity and global level of the epigenetic marker 5-methylcytosinethat we believe is indicative of a metabolic alteration that manifests in progressive neuropathology. Peripheral blood mononuclear cells (PBMCs) were relatively spared in the TgHD minipig, probably due to the lack of detectable mHTT. Our data demonstrate that neuropathologyin the TgHD model has an age of onset of 48 months, and that oxidative damage and electron transport chainimpairment represent later states of the disease that are not optimal for assessing interventions. This article has an associated First Person interview with the first author of the paper.